This course will cover all aspects of new drugs and biologics approved in the preceding 12 month period, together with those that entered phase III clinical trials during the same period. This is a unique course in the curriculum that will discuss the latest on new drugs and biologics. Approximately 50% of the lectures will be delivered using traditional methods, covering new drugs and for the remainder of the classes, pre-selected pharmacy student groups will present their projects in new drugs and biologics. Instruction materials and reference materials will be drawn from Health Canada, FDA, scientific literature and drug information files.

This course will not be offered in the 2022-3 academic year.